Each filer's latest filing for M0740A108 since 12/18/2024, largest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Oramed Pharmaceuticals Inc.
13D
|
20.0% |
5/1/2025
Event 4/24/2025
|
|
| Oramed Pharmaceuticals Inc. | 20.0% | ||
| Oramed Ltd. | 20.0% | ||
| Uzi Sofer 13G | 15.8% |
7/24/2025
Event 12/31/2022
|
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 25 | 960 k | $14.1M |
| 2026 Q2 | 74 | 7.97 M | $100M |
| 2026 Q1 | 53 | 4.06 M | $29.1M |
| 2025 Q4 | 36 | 2.41 M | $11.9M |
| 2025 Q3 | 31 | 1.83 M | $8.26M |
| 2025 Q2 | 25 | 1.59 M | $4.95M |
| 2025 Q1 | 24 | 1.17 M | $2.94M |
| 2024 Q4 | 22 | 1.01 M | $3.13M |
| 2024 Q3 | 24 | 948 k | $2.23M |
| 2024 Q2 | 25 | 1.34 M | $3.36M |
| 2024 Q1 | 28 | 2.44 M | $7.17M |
| 2023 Q4 | 28 | 2.15 M | $6.42M |
| 2023 Q3 | 24 | 975 k | $3.65M |
| 2023 Q2 | 21 | 949 k | $4.11M |
| 2023 Q1 | 17 | 1.01 M | $2.91M |
| 2022 Q4 | 15 | 544 k | $1.70M |
| 2022 Q3 | 19 | 697 k | $4.01M |
| 2022 Q2 | 15 | 654 k | $5.92M |
| 2022 Q1 | 13 | 447 k | $5.28M |